论文信息 - Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series - 字舞流文

Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series

J. Bakker | R. V. Schaik | B. Koch | T. Gelder | N. Hunfeld | M. Egal | J. Weigel

[1] R. McPherson,et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study , 2015, The Pharmacogenomics Journal.

[2] A. McLachlan,et al. Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[3] D. Tregouet,et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients , 2011, European Journal of Clinical Pharmacology.

[4] P. Hoogerbrugge,et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. , 2008, Therapeutic drug monitoring.

[5] J. Donnelly,et al. Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.